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Abstract 
In this work, the robustness of the sample preparation procedure for the determination 
of six tranquillizers (xylazine, azaperone, propionylpromazine, chlorpromazine, 
haloperidol and azaperol) and a beta-blocker (carazolol) in animal muscle by LC/MS-
MS was assessed through the experimental design methodology. A 7 4III2
 fractional 
factorial design was performed to evaluate the influence of seven variables on the final 
concentration of the seven drugs in the samples, in accordance with what is laid down 
in Commission Decision No 2002/657/EC. The variation considered for each of those 
seven factors is likely to happen when preparing the samples, being the values chosen 
as level −1 the nominal operating conditions. The results of the experimentation were 
evaluated from different statistical strategies, such as hypothesis testing using an 
external variance previously estimated, Lenth‟s method and Bayesian analysis. Both 
Lenth‟s and Bayes‟ approaches enabled to determine the effect of every variable even 
though no degrees of freedom were left to estimate the residual error. The same 
conclusion about the robustness of the extraction step was reached from the three 
methodologies, namely, none of the seven factors examined influenced on the method 
performance significantly, so the sample preparation procedure was considered to be 
robust. 
Keywords 
Robustness; tranquillizer; liquid chromatography-tandem mass spectrometry; 
Commission Decision No 2002/657/EC; Lenth‟s method; Bayesian analysis. 
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1. Introduction 
Assessing the potential sources of variability in one or several responses of an 
analytical procedure must be a key part of method development. This involves making 
                                                 
1
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2
 International conference on harmonization of technical requirements for Registration of 
pharmaceuticals for human use (ICH), International Union of Pure and Applied Chemistry 
(IUPAC), liquid chromatography coupled to tandem mass spectrometry (LC/MS-MS), xylazine 
(XYL), azaperone (AZA), propionylpromazine (PROP), chlorpromazine (CHLOR), haloperidol 
(HAL), azaperol (AZOL), carazolol (CAR), solid-phase extraction (SPE), maximum residue limit 
(MRL), internal standard (IS), atmospheric pressure chemical ionization (APCI), positive ion 
electrospray (ESI
+
), multiple reaction monitoring (MRM), least squares (LS), variance inflation 
factor (VIF).  
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2 
deliberate and small changes in nominal experimental conditions and investigating their 
subsequent effect on performance to identify the variables with the most significant 
effect and ensure that they are closely controlled when using the method [1]. 
From this perspective, two terms referring to the evaluation of the method performance 
still coexist within the scientific vocabulary: robustness and ruggedness. They have 
often been used as synonyms [2,3,4,5], but a distinction between both has also been 
drawn in accordance with their information about different features of an analytical 
method: its practicability and stability related to experimental physicochemical variables 
that are internal to the method (robustness) and its interlaboratory transferability when 
the variables under study are external to the method (ruggedness) [6,7,8]. In this 
sense, the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH) defines the robustness of an 
analytical procedure as “a measure of its capacity to remain unaffected by small, but 
deliberate variations in method parameters and provides an indication of its reliability 
during normal usage” [9]. On the other hand, the United States Pharmacopeia and The 
National Formulary has adopted the ICH definition of robustness and defines the 
ruggedness of an analytical method as “the degree of reproducibility of test results 
obtained by the analysis of the same samples under a variety of conditions such as 
different laboratories, analysts, instruments, lots of reagents, elapsed assay times, 
assay temperatures, or days " [10]. However, there is still some confusion in scientific 
journals, guidelines and monograph literature regarding the use of these words when 
applied to analytical methods [11]. 
Information about ruggedness/robustness should be indicated in the laboratory 
procedure [1]. Anyway, the strategy to be followed in a robustness and/or ruggedness 
test is the same. It involves performing a screening study usually by means of 
experimental designs after the identification of the potentially influential factors and the 
definition of their variation ranges and of the responses to be determined. At this point, 
conducting either a Plackett–Burman design [12] or a fractional factorial design, as in 
the Youden test [13], is the most frequently used procedure for robustness/ruggedness 
evaluation. The choice of the design to be performed depends on the purpose of the 
test and on the number of factors to be examined [4]. Due to the minimum time and 
analytical effort required, Commission Decision (EC) No 2002/657 [14] encourages the 
application of the Youden approach to the compulsory verification of that performance 
characteristic both in screening and confirmatory methods for the monitoring of certain 
substances and residues thereof in live animals and animal products. Many examples 
in this field can be found in the literature [6,15,16,17,18,19]. The Eurachem Guide to 
Method Validation and Related Topics [1] recommends, whenever possible, the 
evaluation of the ruggedness/robustness of a method by using the Youden test. IUPAC 
[2] also recognizes the strategy described by Youden as adequate to study the 
ruggedness of an analytical method. 
This work shows the evaluation of the performance of the sample preparation step prior 
to the simultaneous determination of seven drugs in animal muscle by liquid 
chromatography coupled to tandem mass spectrometry (LC/MS-MS). More precisely, 
the substances analysed were five tranquillizers (xylazine (XYL), azaperone (AZA), 
propionylpromazine (PROP), chlorpromazine (CHLOR) and haloperidol (HAL)), one of 
the metabolites of azaperone (azaperol (AZOL), which is derived from the former by 
reduction) and a blocker agent of the β-adrenergic receptor (carazolol (CAR)). Their 
chemical structures are depicted in Fig. 1. As the sample preparation stage includes 
sampling, pretreatment and solid-phase extraction (SPE) steps, it will be quite likely to 
be responsible of the highest errors in the determination. So, the effect of seven factors 
related to the sample preparation procedure on the final concentration of every drug in 
the sample was examined through an eight-experiment Youden design. These factors 
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were deliberately changed between nominal and extreme conditions that represented 
the variability that may well occur when performing routine analyses. The results 
arising from the experimental plan were interpreted from several statistical 
methodologies in order to assess the robustness of the extraction step. 
As the proposed design was saturated, an independent estimation of the experimental 
error as standard deviation at a previous stage of the method development was used to 
evaluate the significance of the factors. In addition, Lenth‟s and Bayes‟ approaches [20] 
have also been applied for drawing conclusions on the robustness/ruggedness of the 
sample preparation stage. 
Veterinary medicinal products are necessary to ensure animal health and welfare, but 
their administration to food-producing animals may leave residues in them. This is the 
case of sedatives, which are often used in animal production, especially in pigs. These 
are more aggressive than other farm animals and particularly sensitive to stress during 
handling and, more specifically, during their transport to the slaughterhouse. Not 
palliating all this stress will result in high premature mortality and meat of poorer quality 
called Pale Soft Exudative [21,22], so pigs are usually injected with sedatives a few 
hours before slaughtering to calm them down. Due to their potential effect on the 
activity of the human nervous system, residues of these drugs in foodstuffs of animal 
origin constitute a hazard to human health, which makes their analytical control 
necessary. Consequently, European legislation on this matter has been developed. As 
part of it, Commission Regulation (EU) No 37/2010 [23] establishes maximum residue 
limits (MRLs) for some allowed pharmacologically active substances depending on the 
animal species and on the target tissue according to the procedures in Regulation (EC) 
No 470/2009 [24]. Prohibited pharmacologically active substances for which a MRL 
cannot be established are also listed in [23]. In the specific case of the sedatives 
analysed in this study, the MRL for azaperone, as the sum of azaperone and azaperol, 
is 100 μg kg-1, and that for carazolol is 5 μg kg-1, both values in porcine muscle tissue, 
while the use of chlorpromazine in food-producing animals is not allowed. 
The rules laid down in Commission Decision No 2002/657/EC [14] require confirmatory 
methods for organic residues such as those from veterinary drugs or contaminants to 
provide information on the chemical structure of the analyte. In fact, the European 
Union considers mass spectrometry the most suitable analytical tool for a correct 
identification of these compounds [25]. When full-mass spectra are not recorded, a 
system of identification points with different requirements for prohibited substances and 
for those with MRLs (listed in Group A or B, respectively, of Annex I of Directive 
96/23/EC) shall be used to interpret the data. 
2. Theory 
Full factorial designs are useful for experimenting with relatively few factors.  As the 
number of factors in a 2k factorial design increases, the number of runs required for its 
consecution rapidly outgrows the resources of most experimenters. But it is possible to 
run only a fraction of the full factorial set that provides nearly as much information as in 
the corresponding full factorial design if it can be reasonably assumed that certain high-
order interactions are negligible. These fractional factorial designs are among the most 
widely used types of designs for product and process design and improvement, and 
industrial/business experimentation [26], being also greatly applied in screening studies 
such as those for evaluating the robustness/ruggedness of an analytical method.  
A 2k fractional factorial design containing 2k−p runs is called a 1/2p fraction of the 2k 
design or, more simply, a 2k−p fractional factorial design, where k is the number of 
factors considered and p the number of independent generators selected for the 
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4 
construction of the design, being p < k. More information about the construction of 
fractional factorial designs can be found in [26,27].  
The resolution of a fractional factorial design shows how the estimated effects are 
confounded. In particular, resolution III fractional factorial designs  k pIII2   are those in 
which no main effects are aliased with any other main effect, but they are aliased with 
two-factor interactions and some two-factor interactions may be aliased with each other 
[26]. So, as main effects can be estimated only in the absence of interaction effects, 
these will be considered to be negligible when estimating those. 
Two-level resolution III designs can be constructed to evaluate k = (N − 1) factors with 
N runs, being N a power of 2. An example of resolution III fractional factorial designs is 
the robustness test introduced by Youden and Steiner for analytical chemistry [13]; this 
kind of experimental designs was well-established in other fields of science, though, 
such as in agriculture since the 1920s [28]. 
The Youden robustness test makes use of a two-level 7 4III2
 fractional factorial design to 
study the influence of up to seven factors in eight experiments. This is the strategy 
recommended by different international regulatory bodies to check the 
robustness/ruggedness of an analytical method [1,2,13,14,29]. For the assignment of 
the two levels of every factor, although a symmetrical interval around every nominal 
operating condition (encoded as 0) between two extreme levels (encoded as −1 and 
+1, respectively) is often set, it is also stated in [1,2,13,14,29] that the different 
influential variables should be changed from their nominal values (encoded as −1) to 
those extreme (encoded as +1) meaning a slight change with regard to the nominal 
operating conditions. The existence of curvature in any of the monitored factors is not 
expected because the variation from level −1 to level +1 is quite small. 
When seven factors are evaluated from eight runs performed following the 
experimental plan of the 7 4III2
 fractional factorial design proposed by Youden and 
Steiner, as no interactions are taken into account, the mathematical model posed to 
express the underlying relation between the response under study y and the seven 
factors considered is, in codified variables: 
0 1 1 2 2 3 3 4 4 5 5 6 6 7 7y x x x x x x x            (1) 
where ε is the experimental error and the variable ix , i = 1,...,7, equals either −1 or +1 
whether the i-th factor is at either nominal or extreme level, respectively.   
Since the model in Eq. (1) consists of eight coefficients and only eight runs are 
available, the effect of every factor will thus be calculated rather than estimated as 
follows: 
   
i
y 1 y 1
4
  
 
 
 (2) 
where  y 1 and  y 1 represent the sums of the responses where factor ix  is at 
(+1) and (−1) level, respectively. There will be no degrees of freedom left to estimate 
the experimental error ε either, so the evaluation of the statistical significance of either 
the model in Eq. (1) or its coefficients by a hypothesis test will not be possible from the 
design. At this point, several alternatives are available. 
2.1. Using an external variance for the estimation of the residual error 
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5 
The first choice is to have an estimation of the experimental error as standard deviation 
s, which could have been calculated either from previous tests with the analytical 
procedure of interest or by performing more experiments (replicates of one or more 
design points). Both choices will make it possible to estimate the significance of the 
coefficients in Eq. (1) thanks to the following hypothesis test:  
H0: βi = 0 (There is not effect of the factor i) (3) 
Ha: βi ≠ 0 (There is effect of the factor i)  
The critical region (CR) of this hypothesis test, at a 95% confidence level, is defined as 
CR 1.96 or 1.96  for i =1,...,7
s s 
   
    
  i i
i i  (4) 
where the value of the standard deviation 
i
s  is calculated from Eq. (5), being n the 
number of runs in the experimental design (n = 8 in this work) and s the experimental 
error externally estimated. 
iβ
s
s =
n
 (5) 
2.2. Lenth‟s method 
Another alternative means the use of statistical approaches that do not need a previous 
estimation of the residual error. The standard procedure for the analysis of an 
unreplicated two-level factorial design is the normal (or half-normal) plot of the 
estimated factor effects. However, unreplicated designs are so widely used in practice 
that many formal analysis procedures have been proposed to overcome the subjectivity 
of the normal probability plot [26]. One of these options is Lenth‟s method [20,26]. This 
is based on the idea that, if none of the factors is active, the coefficients of the model in 
Eq. (1), except for the constant term 0 , will have values around 0, whereas the 
coefficient of an active factor will be different from 0. So, if the absolute values of those 
coefficients are considered, an initial estimate of the coefficient standard deviation s is 
obtained by arranging those absolute values in increasing order and multiplying their 
median by 1.5. Any coefficient whose absolute value is greater than 2.5s  is then 
removed from the list and the whole procedure is repeated until no further coefficient is 
rejected. Let c denote the number of coefficients that remain in the end. A coefficient 
will be active at a 5% significance level if it lies out of the 
interval  0.025, 3 0.025, 3t s ,t s  c c , being 0.025, 3t c  the value of a Student‟s t-distribution for a 
probability equal to 0.025 and c/3 degrees of freedom. 
2.3. Bayesian approach 
In line with Section 2.2, a second option when no estimation of the experimental 
variance is possible is the Bayesian analysis of the coefficients i [20]. This procedure 
is based on calculating the a posteriori probability that the respective factor is active. 
This involves that: i) only a fraction α (between 0.10 and 0.40) of the factors is active; ii) 
inactive coefficients are assumed to follow a normal distribution with mean 0 and 
constant variance; and iii) the coefficients of the active factors are also supposed to be 
normally distributed, but now with a higher variance, so that the ratio k of the variance 
of the active factors to that of the inactive ones ranges from 5.0 to 15.0. By changing α 
and k, it is possible to determine both the maximum and the minimum a posteriori 
probabilities of every factor being active. 
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3. Material and methods 
3.1. Reagents and chemicals 
HPLC-grade methanol, analytical-grade ethanol, HPLC-grade acetonitrile, formic acid 
(98-100% purity), 32% ammonia solution and analytical-grade potassium dihydrogen 
phosphate were all purchased from Merck (Darmstadt, Germany). Analytical-grade 
orthophosphoric acid and potassium hydroxide (both 85% purity) were supplied by 
Panreac (Barcelona, Spain).  
A solution of phosphate buffer (0.1 M, pH 6, 1 L) was prepared by dissolving potassium 
dihydrogen phosphate into Milli-Q water and adjusting pH to 6 with 10 M potassium 
hydroxide. 
Azaperol (97% minimum purity) was supplied by Dr. Ehrenstorfer GmbH (Augsburg, 
Germany). Xylazine hydrochloride, haloperidol, chlorpromazine hydrochloride, 
propionylpromazine hydrochloride, azaperone and azaperone-d4 (used as the internal 
standard (IS) for both azaperone and azaperol) were obtained from Sigma-Aldrich 
(Steinheim, Germany), all of them with a 98% minimum purity. Chlorpromazine-d3 (IS 
for both chlorpromazine and propionylpromazine) and haloperidol-d4 (IS for haloperidol, 
carazolol and xylazine) were purchased from LGC Standards (Teddington, UK), both 
with a 98% minimum purity. Carazolol (Suacron®, 98% minimum purity) was a 
generous gift from Divasa-Farmavic, S.A. (Barcelona, Spain). Whenever needed, ultra-
pure water was obtained from a Milli-Q water purification system (Millipore, Bedford, 
MA, USA). 
3.2. Standard solutions  
Stock solutions of xylazine, azaperone, propionylpromazine, chlorpromazine, 
haloperidol, azaperol and carazolol at 100 mg L-1 and individual stock solutions of 
azaperone-d4 (100 mg L
-1), chlorpromazine-d3 (1 mg L
-1) and haloperidol-d4 (1 mg L
-1) 
were prepared in ethanol and stored in amber bottles at 4 ºC. Concentrations of these 
analytes must be referred to their free forms, not to the hydrochloride ones.  
Two working solutions were prepared by further dilution in ethanol: one containing the 
seven non-deuterated sedatives at the following concentrations: 100 μg L-1 for xylazine, 
2500 μg L-1 for azaperone, 150 μg L-1 for propionylpromazine, 100 μg L-1 for 
chlorpromazine, 50 μg L-1 for haloperidol, 2000 μg L-1 for azaperol and 125 μg L-1 for 
carazolol; and the other with the three ISs at concentrations of 2500 μg L-1 for 
azaperone-d4, 200 μg L
-1 for chlorpromazine-d3 and 40 μg L
-1 for haloperidol-d4. Both 
solutions were stored in amber bottles at 4 ºC. 
3.3. Sample pretreatment and purification procedure 
For the evaluation of the seven influential factors listed in Table 1, eight muscle 
samples were prepared according to the experimental plan of the Youden design 
shown in Table 2 (in codified variables). In addition, six matrix-matched calibration 
standards including a blank underwent the same pretreatment process, being the 7 
variables selected as factors set at their nominal conditions (level −1). In all cases, 5 g 
of homogenised animal muscle was weighed in a 50 mL polypropylene tube and then 
fortified with the three ISs by adding a 50 μL aliquot of the working internal standard 
solution. Next, 100 μL of the working standard solution of the sedatives was added to 
all robustness samples, while five of the six matrix-matched standards were spiked, 
respectively, with 50, 100, 200, 300 and 400 μL of that solution. Before the preparation 
of both the samples and the standards, it had been checked that the animal muscle 
tissue used as matrix was completely free of the analytes under study. This avoided 
performing additional experimentation for the calculation of recovery. 
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7 
10 mL (level −1) or 9 mL (level +1) of a newly prepared (level −1) or a one-month-aged 
(level +1) phosphate buffer solution was pipetted to every sample and the mixture was 
stirred in a vortex mixer for 30 s. After 10 min in an ultrasonic bath, 3 mL of 1% 
orthophosphoric acid was added, and every sample was vortex mixed again for 30 s 
and then centrifuged for 10 min at 6800 rpm at room temperature. The supernatant of 
every homogenate was clarified using a Millex-AP prefilter coupled to a 20 mL syringe. 
The purification step by solid-phase extraction (SPE) was performed either manually 
(level −1) or automatedly (level +1). SPE cartridges were first conditioned with 3 mL of 
methanol and then equilibrated with 3 mL of Milli-Q water. After every sample filtrate 
had been loaded, cartridges were rinsed with 3 mL of 1 M formic acid and next with 3 
mL (level −1) or 3.5 mL (level +1) of a methanol/1 M formic acid (55/45 v/v) washing 
solution. After drying by passing an air stream under vacuum for 10 min, elution of the 
analytes and the internal standards was performed with 4 mL (level −1) or 4.5 mL (level 
+1) of a newly prepared (level −1) or one-week-aged (level +1) eluting solution 
(ammonium hydroxide/ethanol 2/98 v/v). Each eluate was collected in a 15 mL amber 
tube, evaporated to dryness under nitrogen at 38 ºC, reconstituted with 250 μL of 30% 
acetonitrile and placed in an ultrasonic bath for 5 min. Every final extract was clarified 
through a 0.22-μm nylon filter coupled to a 1 mL syringe, and the filtrate was 
transferred to an insert contained into a vial for LC/MS-MS analysis. 
This sample pretreatment and purification procedure had been optimized prior to 
carrying out the robustness study described in this work. The thorough cleanup step 
performed before LC/MS-MS analysis, together with the use of three deuterated 
internal standards and matrix-matched calibration, helped to avoid the ionization-
suppression/enhancement problem as far as possible. 
3.4. Instrumental 
Millex-AP prefilters were obtained from Millipore Corporation (Bedford MA, USA). A 
Jouan C3i centrifuge (Thermo Electron Corporation, San Jose, CA, USA) was used. 
The vacuum manifold used for the SPE step was purchased from Waters Corporation 
(Milford, MA, USA). SPE cartridges were 300 mg/6 mL Varian Bond Elut LRC Certify® 
(Agilent Technologies, Waldbronn, Germany). 
3.5. LC/MS-MS analysis  
Chromatographic separation was carried out on an Agilent 1200RR series liquid 
chromatograph (Agilent Technologies, Waldbronn, Germany) equipped with a binary 
pump, a degasser, an autosampler and a column heater, in which a Gemini NX C18 
column (50 mm×2mm I.D.; particle size, 3 μm; Phenomenex, Macclesfield, UK) was 
placed at 30 ºC. Two mobile phases were used in a gradient program, in which the 
mobile phase A consisted of acetonitrile containing 0.5% ammonium hydroxide and 
mobile phase B consisted of water containing 0.5% ammonium hydroxide. The initial 
composition was 30% A and 70% B, which was increased linearly to 85% A in the first 
7 min, held at these conditions for 2 min and returned to the initial composition from 
minute 9 to minute 11. The column was then equilibrated in these conditions for 4 min 
before the next injection, being the total run time 15 min. The flow rate was set at 0.3 
mL min-1 and the injection volume was 10 μL. 
Tandem mass spectrometry was performed on an Agilent 6410B triple quadrupole 
mass analyzer with a multimode ionization source which was programmed to operate 
in mixed conditions of atmospheric pressure chemical ionization (APCI) and positive 
ion electrospray (ESI+). The source temperature was held at 250 ºC and the capillary 
voltage was set at 4300 V. Nitrogen was used both as nebuliser and collision gas. 
Analytes were detected using the multiple reaction monitoring (MRM) mode with a 
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dwell time of 70 ms per ion. Both Q1 and Q3 quadrupoles were maintained at unit 
resolution. As can be seen in Table 3, for the confirmation of every drug, its molecular 
ion was selected as the precursor ion and two transitions thereof were monitored, while 
quantification was carried out with the most intense transition. Regarding the three 
internal standards, only one transition from its corresponding molecular ion was 
considered in each case.  
3.6. Software 
The experimental design performed was constructed and interpreted using NEMRODW 
[30]. All the regression lines were estimated and validated using STATGRAPHICS 
Centurion XVI [31]. 
4. Results and Discussion 
As one of the last stages in the development of a method for the multiresidue 
determination of seven drugs in animal muscle by LC/MS-MS, the robustness of the 
sample preparation step was assessed by means of the strategy proposed by [13] and 
recommended by the legislation in force in the European Union [14]. The seven 
experimental factors evaluated were: 1) Analyst; 2) Way of performing the SPE stage 
by using either a multistation vacuum manifold or an automated extraction system; 3) 
Time elapsed between the preparation of the eluting solution, whose expiry was set to 
1 week, and the day of analysis; 4) Time elapsed between the preparation of the 
phosphate buffer solution, whose expiry was set to 1 month, and the day of analysis; 5) 
Volume of the phosphate buffer added to the samples; 6) Volume of the 
ammonia/ethanol eluent in SPE; 7) Volume of the methanol/formic acid rinsing solution 
in SPE. Table 1 shows these seven factors as well as the two levels chosen for each of 
them. As commented in Section 2 and in accordance with the procedures in 
[1,2,13,14,29], the nominal operating conditions of the method were selected as level 
−1 for every factor. 
Seven experimental responses were considered, namely the concentration of the 
seven drugs in a muscle sample that had been fortified with 100 μL of the working 
standard solution. The concentration of each sedative in every muscle sample was 
determined from the corresponding least squares (LS) linear regression of 
standardized peak area (calculated as the ratio between the absolute peak area of the 
analyte of interest and that of its internal standard) versus true concentration. These 
seven regression models were estimated from a calibration set of six matrix-matched 
standards, each of them corresponding, besides a blank, to the addition of 50, 100, 
200, 300 and 400 μL of the working standard solution, respectively. The calibration 
range of every analyte was thus 0 – 6.92 µg kg-1 for xylazine, 0 – 202.00 µg kg-1 for 
azaperone, 0 – 11.15 µg kg-1 for propionylpromazine, 0 – 7.26 µg kg-1 for 
chlorpromazine, 0 – 4.00 µg kg-1 for haloperidol, 0 – 160.00 µg kg-1 for azaperol, 0 – 
10.03 µg kg-1 for carazolol. The matrix-matched standards were pretreated and 
analysed under the nominal operating conditions of the method (see Sections 3.3 and 
3.5). 
The influence of the seven factors considered on the final concentration of every drug 
in a muscle sample was studied through a 7 4III2
 fractional factorial design consisting of 
eight experiments. As can be seen in Table 2, the resulting experimental matrix 
matches up with that of the Youden proposal by multiplying by (−1) every element of 
the matrix. The suitability and great quality of this experimental design to be performed 
is well-known. As its information matrix (and thus its dispersion matrix) is a diagonal 
matrix, the orthogonality of the design is ensured. Because of this orthogonal design 
structure, all main effects would be estimated independently, and the variance inflation 
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9 
factors (VIFs) of all the coefficients in the model of Eq. (1), which describes the 
relationship between every response and the seven factors monitored, were equal to 1. 
As this is the best value for a VIF, the estimates of those coefficients would be the most 
precise possible ones. 
Once the whole experimentation had been carried out, the presence of both all the 
analytes and the internal standards in every sample was confirmed from their 
precursor-to-product transitions, listed in Table 3. Then, the standardized peak area of 
every analyte in every run was calculated from its most intense transition, and the 
seven LS calibration models necessary to determine the response (concentration of 
every drug) for every experiment of the design were estimated. The equations of these 
linear regression models “standardized peak area versus true concentration” figure in 
Table 4. A LS linear regression „„predicted concentration versus true concentration‟‟ 
was also performed for every analyte in order to assess the trueness of the analytical 
method; the equations of these seven accuracy lines appear in the last column of Table 
4. As the estimates of the intercept (b0) and the slope (b1) of a linear regression are 
correlated, the joint confidence region for both parameters of every accuracy model 
was estimated at α = 0.05. The seven resulting ellipses are plotted together in Fig. 2. 
As can be seen there, the size of the seven ellipses was clearly different; this is due to 
the fact that the area of a joint confidence region is directly related to the residual 
variance of the model: the lower the value of the residual standard deviation (see Table 
4, last column), the greater the quality of the precision on the predictions and the 
smaller the area within the confidence contour. The orientation of the ellipses for 
azaperone (in dark blue) and azaperol (in magenta), both standardized by the same IS 
(azaperone-d4), differed from that of the confidence regions for the rest of the analytes. 
The reason was the use of a wider calibration range around the MRL of 100 μg kg-1 
established in [23] for the sum of azaperone and azaperol, so higher values of the 
standard deviation of b0 were obtained in both cases. Anyway, as the centroid of all the 
ellipses, represented by the least squares estimator (b0,b1), was statistically equal to 
(0,1), it could be asserted that the trueness of the analytical method was ensured jointly 
for the seven drugs under study at a 95% confidence level. 
The decision limit (CCα) and the detection capability (CC) of the analytical method for 
azaperone, azaperol and carazolol at its respective MRL with α =  = 0.05 were 
estimated from the corresponding calibration model as it is laid down in [14]. The 
values of CCα and CC achieved for these three analytes when 1 replicate is 
performed were, respectively, 106.5 μg kg-1 and 112.5 μg kg-1 for azaperone, 104.4 μg 
kg-1 and 108.3 μg kg-1 for azaperol, and 6.12 μg kg-1 and 7.14 μg kg-1 for carazolol. 
The eight runs that made up the experimental matrix together with the values of the 
seven responses (concentration of every drug) are gathered in Table 2. As the 
experimental design conducted was saturated, the eight coefficients i  of each of the 
seven models could be exactly determined from Eq. (2); the values of 1 to 7 , related 
to the effect of the factors 1 to 7 on every response, are shown in Table 5. However, an 
estimate of the variance of the random term ε in Eq. (1) could not be achieved, so the 
statistical significance of neither the model nor that of its coefficients could be 
evaluated through the corresponding hypothesis test. For this work, the reproducibility 
standard deviation at a concentration c had been previously estimated for every 
analyte at an earlier stage of the validation process of the method. This standard 
deviation s, external to the experimental design, made it possible to determine whether 
the variations considered for the seven factors had a significant effect on every 
response thanks to the hypothesis test posed in Section 2.1.  
For every analyte, the reproducibility standard deviation s at a specific concentration c, 
together with the value of the statistic s
ii 
 for the significance of each coefficient i , 
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is shown in Table 5. For xylazine, propionylpromazine and haloperidol, the value of c 
corresponded to the final concentration of every analyte in a muscle sample fortified 
with 100 μL of the working standard solution of these sedatives; for chlorpromazine, 
which is a banned substance as tranquillizer in the European Union, and azaperone, 
azaperol and carazolol, with values of MRL established in porcine muscle [23], the 
value of c was exactly twice the decision limit (CCα) of the method.  
Taking the hypothesis test posed in Eq. (3) into account, there was not enough 
experimental evidence to reject the null hypothesis (H0) in any case since no statistic 
value lay into the corresponding critical region (see Eq. (4)). Therefore, it could be 
concluded that the performance of the method was not influenced by the changes in 
the seven variables under study and the sample preparation procedure was robust. 
Other alternatives for the evaluation of potentially influential factors when an estimation 
of the experimental variance is not used are Lenth‟s method and Bayesian analysis of 
the coefficients i , both of which were also applied in this work. These two strategies, 
which are explained in Section 2.2 and 2.3, respectively, are especially useful for the 
interpretation of saturated designs if an estimate of the residual error ε is not available. 
The results of the application of Lenth‟s method are reflected in the last column of 
Table 5, where the confidence interval  0.025, 3 0.025, 3-t  s ,t  sc c  estimated through this 
approach for every analyte is collected. It is clear that, in all cases, none of the seven 
coefficients 1 to 7  (also in Table 5) lay out of the corresponding interval, so all factors 
were non-significant and the sample preparation step was considered to be acceptably 
robust.  
The second option applied for testing the significance of the effects was the Bayesian 
analysis of the coefficients of every model. As a result, the probabilities of each effect 
being active on every response (analyte) were calculated a posteriori for different 
values of k and α. Fig. 3 shows the range of a posteriori probabilities of significance 
plotted as a solid box between the maximum and minimum values of this probability. 
This range was determined for every analyte and every coefficient in Eq. (1) estimating 
the effect of a factor (β1,…,β7), so 49 ranges of a posteriori probabilities of significance 
are depicted in Fig. 3. 
The maximum was below 60% in 35 cases (coefficients), between 64% and 80% in 
another 5, and higher than 80% for the remaining 9 cases. However, as the a posteriori 
probability of significance may really have any value between the minimum and the 
maximum, no factor gave clear proof of being active on the determination of none of 
the seven analytes. Only the way of performing the SPE step (factor 2) could be 
considered the most likely to be significant, since its a posteriori probability varied from 
nearly 45% to 95% in the case of azaperol, although it must be borne in mind that its 
real probability of significance might have any value within this range. As no effect had 
a minimum a posteriori probability of being significant close to 100%, no evidence of 
clearly influencing factors was provided, so the robustness of the sample preparation 
step could not be rejected. This conclusion exactly coincides with that drawn from each 
of the other two methodologies employed for the interpretation of the results of the 
Youden experimental design performed in this work (hypothesis testing and Lenth‟s 
method). 
5. Conclusions 
The robustness of the sample preparation stage for the determination of xylazine, 
azaperone, propionylpromazine, chlorpromazine, haloperidol, azaperol and carazolol in 
muscle tissue by LC/MS-MS has been verified by means of a 7 4III2
 fractional factorial 
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design, following the procedure recommended by Commission Decision No 
2002/657/EC. After carrying out the eight runs that make up the experimental plan, the 
influence of seven factors involved in the sample preparation prior to analysis (namely, 
analyst, way of performance of the SPE step, age of both the phosphate buffer and 
eluent, volumes needed of the buffer, SPE washing solution and SPE eluent) has been 
evaluated by means of different statistical strategies, such as hypothesis testing, 
Lenth‟s method and Bayes‟ analysis, the latter two allowing to draw conclusions on 
which factors are active even though no estimate of the residual error is available. 
Whatever the approach used to interpret the results of the experimental design, the 
sample preparation procedure under study has proved to be robust to the small 
variations considered, which can be expected throughout its routine performance. 
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FIGURE CAPTIONS 
Fig. 1 Chemical structures of the seven drugs analysed. 
Fig. 2 Joint confidence region for the intercept (0) and the slope (1) of the 
accuracy line estimated for every analyte at a 5% significance level. (a) 
Xylazine: red line; (b) Azaperone: dark blue line; (c) Propionylpromazine: 
green line; (d) Chlorpromazine: yellow line; (e) Haloperidol: black line; (f) 
Azaperol: magenta line; (g) Carazolol: light blue line. The mean vector (b0, 
b1) of every ellipse is represented by +. 
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Fig. 3 Graphic representation of the results obtained, for each analyte, from the 
Bayesian analysis of the statistical significance of the seven factors 
evaluated (α belongs to the interval [0.10,0.40], while k does to [5.0,15.0]). 
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Table 1 
Experimental domain: factors and selected levels for the evaluation of the robustness of the 
sample preparation step. 
Factor (Units) 
Level 
−1 +1 
1 Analyst Analyst A Analyst B 
2 SPE performance Manual Automated 
3 Age of eluting solution Newly prepared 1 week 
4 Age of phosphate buffer Newly prepared 1 month 
5 Volume of phosphate buffer (mL) 10 9 
6 Volume of eluting solution (mL) 4 4.5 
7 Volume of washing solution (mL) 3 3.5 
 
 
 
 
 
 
Table 3 
Transitions monitored for the determination of the seven analytes and the three internal 
standards by LC/MS-MS. 
Compound Most intense transition Less intense transition 
Xylazine 221.2 > 90.0 221.2 > 164.1 
Azaperone 328.1 > 165.0 328.1 > 121.0 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 
 
19 
 
Propionylpromazine 341.2 > 86.1 341.2 > 58.1 
Chlorpromazine 319.1 > 86.2 319.1 > 58.1 
Haloperidol 376.2 > 165.1 376.2 > 123.2 
Azaperol 330.3 > 121.1 330.3 > 149.2 
Carazolol 299.2 > 116.1 299.2 > 222.1 
Azaperone-d4 332.0 > 169.0 - 
Chlorpromazine-d3 322.2 > 61.0 - 
Haloperidol-d4 380.0 > 169.0 - 
 
 
 
 
 
Table 4 
Calibration models for the quantification of the seven drugs analysed. 
Analyte 
Calibration range
a
 
(µg kg
-1
) 
Aanalyte/AIS
b
 = f(ctrue) 
(R
2
; syx) 
cpred = b0 + b1 ctrue 
(R
2
; syx) 
XYL 0 – 6.92 
y = 1.04 + 4.68x 
(98.41%; 1.77) 
y = 5.6 10
-5
 + 1.00x 
(98.41%; 0.38) 
AZA 0 – 202.00 
y = 0.09 + 0.06x 
(99.89%; 0.17) 
y = -1.3 10
-5
 + 1.00x 
(99.89%; 2.84) 
PROP 0 – 11.15 
y = -0.64 + 2.37x 
(99.73%; 0.59) 
y = -5.6 10
-6
 + 1.00x 
(99.73%; 0.25) 
CHLOR 0 – 7.26 
y = -0.06 + 0.67x 
(99.93%; 0.06) 
y = 1.5 10
-5
 + 1.00x 
(99.93%; 0.08) 
HALO 0 – 4.00 
y = -2.5 10
-3
 + 3.99x 
(99.38%; 0.54) 
y = 2.9 10
-5
 + 1.00x 
(99.38%; 0.14) 
AZOL 0 – 160.00 
y = 4.9 10
-3
 + 0.07x 
(99.93%; 0.13) 
y = -1.5 10
-4
 + 1.00x 
(99.93%; 1.86) 
CAR 0 – 10.03 
y = 0.08 + 2.61x 
(98.75%; 1.27) 
y = 7.4 10
-5
 + 1.00x 
(98.75%; 0.49) 
(
a
) n = 6 calibration standards 
(
b
) Standardized peak area of the analyte, calculated as Absolute peak area of the 
analyte/Absolute peak area of its internal standard 
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HIGHLIGHTS 
Robustness study of the sample preparation step to determine sedatives by 
LC/MS-MS 
Seven factors evaluated through a Youden design according to the European 
legislation 
Results interpreted from quite useful methodologies when the residual error is 
unknown 
Lenth‟s and Bayes‟ approaches for robustness testing when performing 
saturated designs 
 
 
 
 
 
 
 
 
 
